| Dokumentenart: | Artikel | ||||
|---|---|---|---|---|---|
| Titel eines Journals oder einer Zeitschrift: | Ophthalmology | ||||
| Verlag: | ELSEVIER SCIENCE INC | ||||
| Ort der Veröffentlichung: | NEW YORK | ||||
| Band: | 112 | ||||
| Nummer des Zeitschriftenheftes oder des Kapitels: | 12 | ||||
| Seitenbereich: | S. 2070-2075 | ||||
| Datum: | 2005 | ||||
| Institutionen: | Medizin > Lehrstuhl für Augenheilkunde | ||||
| Identifikationsnummer: |
| ||||
| Stichwörter / Keywords: | SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY; LESION SIZE; MACULOPATHY; PREVALENCE; SECONDARY; TRIAL; TAP; | ||||
| Dewey-Dezimal-Klassifikation: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin | ||||
| Status: | Veröffentlicht | ||||
| Begutachtet: | Ja, diese Version wurde begutachtet | ||||
| An der Universität Regensburg entstanden: | Ja | ||||
| Dokumenten-ID: | 70351 |
Web of ScienceZusammenfassung
Purpose: To compare the efficacy and safety of early retreatment with verteporfin therapy with that of approved standard verteporfin therapy in neovascular age-related macular degeneration. Design: Prospective, randomized, multicenter clinical trial. Participants: Two hundred three patients with predominantly classic choroidal neovascularization secondary to age-related macular degeneration. ...
Zusammenfassung
Purpose: To compare the efficacy and safety of early retreatment with verteporfin therapy with that of approved standard verteporfin therapy in neovascular age-related macular degeneration. Design: Prospective, randomized, multicenter clinical trial. Participants: Two hundred three patients with predominantly classic choroidal neovascularization secondary to age-related macular degeneration. Methods: Throughout the first 6 months of follow-up, patients received retreatment with verteporfin therapy either every 2 months (group A) or 3 months (group B). From 6 to 12 months, both groups received retreatment at 3-month intervals. Main Outcome Measures: The primary outcome of the study was best-corrected mean visual acuity as measured using the Early Treatment Diabetic Retinopathy Study protocol. The secondary outcomes were percentage of patients losing at least 3 lines of vision, percentage of patients gaining at least 1 line of vision, and lesion size based on the greatest linear dimension (GLD) documented by fluorescein angiography, impact of initial lesion size, and retreatment rate as well as safety. Results: Visual acuity was similar in both groups at baseline with a mean visual acuity of 20/100(-1). During the 12 months of follow-up, mean visual acuity was better in the early retreatment group at all intervals; however, no statistically significant benefit was seen in the overall population at anytime (P > 0.1). At month 12, mean visual acuity was 20/160(+1) in group A and 20/160(-1) in group B. There was a trend for better outcomes in the early retreatment group with regard to loss of less than 3 lines of vision at 12 months (61% vs. 51.7%). No statistically significant difference was seen with regard to lesion size for either group throughout follow-up with a final GLD of the lesion of 2790 mu m (group A) and 2996 mu m (group B). However, subgroup analysis indicated a statistically relevant benefit (P <= 0.004) for patients with small lesions (GLD < 2000 mu m) at baseline receiving early retreatment. Conclusions:. Early retreatment in 2-month intervals did not show a significant overall benefit at 1 year of follow-up compared with the standard regimen. However, smaller lesions seemed to benefit from early retreatment with verteporfin therapy in contrast to larger lesions.
Metadaten zuletzt geändert: 19 Dez 2024 14:54
Altmetric